Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 19/20 | 1.00 |
| ▸ | GSK3B | P49841 | 19/20 | 1.00 |
| ▸ | CDK1 | P06493 | 18/20 | 1.00 |
| ▸ | CCNB2 | O95067 | 17/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 17/20 | 1.00 |
| ▸ | CCNB3 | Q8WWL7 | 17/20 | 1.00 |
| ▸ | CDK5 | Q00535 | 11/20 | 1.00 |
| ▸ | CDK5R1 | Q15078 | 10/20 | 1.00 |
| ▸ | CDK2 | P24941 | 3/20 | 1.00 |
| ▸ | MAPK8 | P45983 | 3/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 2/20 | 1.00 |
| ▸ | CCNE2 | O96020 | 1/20 | 1.00 |
| ▸ | INSR | P06213 | 1/20 | 1.00 |
| ▸ | CFTR | P13569 | 1/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 1/20 | 1.00 |
| ▸ | MAPK3 | P27361 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | MAPK9 | P45984 | 1/20 | 1.00 |
| ▸ | MAPK10 | P53779 | 1/20 | 1.00 |
| ▸ | CCNA1 | P78396 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL490395 | 0.90 | GSK3A (0.97) | GSK3AGSK3BCDK1CCNB2CCNB1 | |
| SCHEMBL13926127 | 0.89 | GSK3A (0.80) | GSK3AGSK3BCDK1CCNB2CCNB1 | |
| SCHEMBL490878 | 0.86 | GSK3A (1.00) | GSK3AGSK3BCDK1CCNB2CCNB1 | |
| Aloisine SCHEMBL79714 | 0.84 | GSK3A (1.00) | GSK3AGSK3BCDK1CCNB2CCNB1 | |
| SCHEMBL27594653 | 0.82 | GSK3A (0.70) | GSK3AGSK3BCDK1CCNB2CCNB1 | |
| SCHEMBL1778932 | 0.82 | GSK3A (0.69) | GSK3AGSK3BCDK1CCNB2CCNB1 | |
| SCHEMBL1779346 | 0.80 | GSK3A (0.70) | GSK3AGSK3BCDK1CCNB2CCNB1 | |
| SCHEMBL1778366 | 0.80 | GSK3A (0.70) | GSK3AGSK3BCDK1CCNB2CCNB1 | |
| SCHEMBL491260 | 0.80 | GSK3A (1.00) | GSK3AGSK3BCDK1CCNB2CCNB1 | |
| SCHEMBL7253117 | 0.80 | GSK3A (0.69) | GSK3AGSK3BCDK1CCNB2CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 692 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | TRAILHEAD BIOSYSTEMS INC (US) | 2026-05-07 | — | — | US | claimed |
| US-12564610-B2 | Human periventricular endothelial cell therapy for neuropsychiatric disorders | THE MCLEAN HOSPITAL CORPORATION (US) | 2026-03-03 | — | — | US | claimed |
| US-20250304916-A1 | METHODS AND COMPOSITIONS FOR GENERATING VASCULAR LEPTOMENINGEAL CELLS | TRAILHEAD BIOSYSTEMS INC (US) | 2025-10-02 | — | — | US | claimed |
| US-20250108070-A1 | METHOD FOR REPROGRAMMING CD8+ T CELLS TO ENHANCE THEIR THERAPEUTIC POTENTIAL AND APPLICATIONS THEREOF | INSTITUT PASTEUR (FR) | 2025-04-03 | — | — | US | claimed |
| US-12187698-B2 | Crystalline forms of C21H22Cl2N4O2 | BIOMED VALLEY DISCOVERIES, INC. (US) | 2025-01-07 | — | — | US | claimed |
| EP-4466342-A1 | METHOD FOR REPROGRAMMING CD8+ T CELLS TO ENHANCE THEIR THERAPEUTIC POTENTIAL AND APPLICATIONS THEREOF | Institut Pasteur (FR) | 2024-11-27 | — | — | EP | claimed |
| US-11999891-B2 | Liquid-crystal medium comprising polymerisable compounds and the use thereof in liquid-crystal displays | MERCK PATENT GMBH (DE) | 2024-06-04 | — | — | US | claimed |
| WO-2023139242-A1 | METHOD FOR REPROGRAMMING CD8+ T CELLS TO ENHANCE THEIR THERAPEUTIC POTENTIAL AND APPLICATIONS THEREOF | INSTITUT PASTEUR (FR) | 2023-07-27 | — | — | WO | claimed |
| US-20220324832-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | VERTEX PHARMACEUTICALS INCORPORATED | 2022-10-13 | — | — | US | claimed |
| US-11377596-B2 | Liquid-crystalline media | MERCK PATENT GMBH (DE) | 2022-07-05 | — | — | US | claimed |
| EP-2346988-B1 | DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS TO THE PANCREATIC ENDOCRINE LINEAGE | JANSSEN BIOTECH INC (US) | 2017-05-31 | — | — | EP | claimed |
| EP-3523331-B1 | CHIMERIC ANTIGEN RECEPTORS FOR THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| EP-3325504-B1 | METHODS FOR IMPROVING THE EFFICACY AND EXPANSION OF IMMUNE CELLS | NOVARTIS AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| EP-4748905-A1 | LIQUID-CRYSTALLINE MEDIUM | Merck Patent GmbH (DE) | 2026-05-27 | — | — | EP | disclosed |
| CN-122080952-A | Liquid-crystalline medium | — | 2026-05-26 | — | — | CN | disclosed |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | BRAINCELLS, INC. (US) | 2007-04-05 | — | — | US | disclosed |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | US | disclosed |
| WO-2007020658-A2 | 'A NOVEL HOMOLOGY MODEL OF THE GLYCOGEN SYNTHASE KINASE 3 ALPHA AND ITS USES THEREOF' | JUBILANT BIOSYS LTD (IN) | 2007-02-22 | — | — | WO | disclosed |
| WO-2006083937-A2 | AGENTS AND METHODS RELATED TO REDUCING RESISTANCE TO APOPTOSIS-INDUCING DEATH RECEPTOR AGONISTS | THE UAB RESEARCH FOUNDATION (US) | 2006-08-10 | — | — | WO | disclosed |
| EP-1388541-A1 | Pyrrolopyrazines as kinase inhibitors | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2004-02-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324832-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | GSK3A 3023/4885GSK3B 2475/4885CDK1 248/4885 |
| US-20250108070-A1 | METHOD FOR REPROGRAMMING CD8+ T CELLS TO ENHANCE THEIR THERAPEUTIC POTENTIAL AND APPLICATIONS THEREOF | ICOS, CD4, NFATC1 | GSK3A 1668/4885GSK3B 1583/4885CDK1 4558/4885 |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | DCX, BDNF, NTRK2 | GSK3A 645/4885GSK3B 629/4885CDK1 635/4885 |
| US-12564610-B2 | Human periventricular endothelial cell therapy for neuropsychiatric disorders | GABRB3, GABRB1, BMP4 | GSK3A 184/4885GSK3B 111/4885CDK1 1965/4885 |
| US-12187698-B2 | Crystalline forms of C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | GSK3A 3023/4885GSK3B 2475/4885CDK1 248/4885 |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | GSK3A 381/4885GSK3B 337/4885CDK1 485/4885 |
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | WNT3A, GSK3B, GSK3A | GSK3A 3/4885GSK3B 2/4885CDK1 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.